NBD AI Bulletin -- Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (the Company, SZ 300357, closing price: 55.46 yuan) announced on November 18 that in view of the Company's intention to issue convertible corporate bonds to non-specific subjects, in accordance with relevant requirements, the Company is obliged to reveal that the Company wasn't imposed any penalty by the China Securities Regulatory Committee (CSRC) or other branches.
According to the semi-annual report of 2020, Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. mainly engages in pharmaceutical manufacturing, accounting for 99.34% of its revenue.
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s chairman and general manager is Hu Gengxi, male, 56 years old, Chinese national, no permanent residence abroad, Ph.D.
Tips on "Stock Trends":
1. The number of shares held by northbound investors decreased by 1.5897 million in the past 30 days, representing 0.33% of the Company's circulating shares.
2. Two batches of institutions (95 in total) conducted researches on the Company in the past 30 days.
(By Tan Yuhan)
Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.